

1 **Virological characteristics of SARS-CoV-2 vaccine breakthrough infections in health**  
2 **care workers**

3

4 Marc C. Shamier<sup>1</sup>, Alma Tostmann<sup>2</sup>, Susanne Bogers<sup>1</sup>, Janet de Wilde<sup>1</sup>, Jeroen Ijpelaar<sup>1</sup>, Willemijn A. van  
5 der Kleij<sup>3</sup>, Herbert de Jager<sup>3</sup>, Bart L. Haagmans<sup>1</sup>, Richard Molenkamp<sup>1</sup>, Bas. B. Oude Munnink<sup>1</sup>, Carsten  
6 van Rossum<sup>2</sup>, Janette Rahamat-Langendoen<sup>2</sup>, Nannet van der Geest<sup>5</sup>, Chantal P. Bleeker-Rovers<sup>4</sup>,  
7 Heiman Wertheim<sup>2</sup>, Marion P.G. Koopmans<sup>1</sup>, Corine H. GeurtsvanKessel<sup>1</sup>

8

9 Affiliations

10 <sup>1</sup>Department of Viroscience, Erasmus Medical Center, Rotterdam, The Netherlands

11 <sup>2</sup>Department of Medical Microbiology, Radboud Centre for Infectious Diseases, Radboud university  
12 medical center, Nijmegen, The Netherlands

13 <sup>3</sup>Department of Occupational Health Services, Erasmus Medical Center, Rotterdam, Netherlands.

14 <sup>4</sup>Department of Internal Medicine, Radboud Centre for Infectious Diseases, Radboud university medical  
15 center, Nijmegen, The Netherlands

16 <sup>5</sup>Department of Occupational Health, Radboud university medical center, Nijmegen, The Netherlands

17

18 Corresponding authors:

19 *email* [c.geurtsvankessel@erasmusmc.nl](mailto:c.geurtsvankessel@erasmusmc.nl)

20

21 **Abstract**

22 **Background:** SARS-CoV-2 vaccines are highly effective at preventing COVID-19-related morbidity and  
23 mortality. As no vaccine is 100% effective, breakthrough infections are expected to occur.

24 **Methods:** We analyzed the virological characteristics of 161 vaccine breakthrough infections in a  
25 population of 24,706 vaccinated healthcare workers (HCWs), using RT-PCR and virus culture.

26 **Results:** The delta variant (B.1.617.2) was identified in the majority of cases. Despite similar Ct-values, we  
27 demonstrate lower probability of infectious virus detection in respiratory samples of vaccinated HCWs  
28 with breakthrough infections compared to unvaccinated HCWs with primary SARS-CoV-2 infections.  
29 Nevertheless, infectious virus was found in 68.6% of breakthrough infections and Ct-values decreased  
30 throughout the first 3 days of illness.

31 **Conclusions:** We conclude that rare vaccine breakthrough infections occur, but infectious virus shedding  
32 is reduced in these cases.

33

34

## 35 **Introduction**

36 Once COVID-19 vaccines became available, health care workers (HCWs) were among the first groups to  
37 be vaccinated and reach high vaccine coverage. Registered vaccines have been highly effective in  
38 preventing clinically significant coronavirus disease 2019 (COVID-19), caused by severe acute respiratory  
39 syndrome coronavirus 2 (SARS-CoV-2)<sup>1</sup>, and have shown to reduce the incidence of  
40 infections<sup>2,3</sup>. However, mild breakthrough infections in a small percentage of vaccine recipients have been  
41 described<sup>4-9</sup> which is not surprising as none of the registered vaccines will provide sterile immunity against  
42 infection<sup>10-13</sup>. In a setting of mass vaccination, the BNT162b2 vaccine was highly effective (92%) at  
43 preventing infection from 7 days after the second dose<sup>14</sup>, but a recent study from Israel described vaccine  
44 breakthrough infections in 39 health care workers vaccinated with the BNT162b2 mRNA vaccine. The  
45 alpha variant was identified as the main causative strain and a majority of cases presented low Ct-values  
46 (<30), indicating probable infectivity<sup>4</sup>. For the single dose Ad26.COV2.S adenoviral vector vaccine, a phase  
47 IV study reported a 76.1% effectiveness to prevent infection from 14 days after vaccination<sup>15</sup>. The  
48 effectiveness against infection with the delta (B.1.617.2) variant was 88% for the BNT162B2 vaccine and  
49 67% for the ChAdOx1 vaccine, moderately lower than against infection with the alpha (B.1.1.7) variant<sup>16</sup>.

50 Up to present, little is known about the virological kinetics of SARS-CoV-2 breakthrough infections, and  
51 the role of the vaccinated host in the transmission cycle. Better understanding of the dynamics of  
52 breakthrough infections is essential to define infection prevention and (public) health policies during the  
53 next phase of the pandemic. In this study, we report the virological findings of 161 vaccine breakthrough  
54 infections occurring from April to July 2021 in the Netherlands. The infections occurred in HCWs working  
55 in two tertiary care hospitals, who were immunized with various mRNA and viral vector vaccines.  
56 Infections were caused predominantly by the SARS-CoV-2 delta variant and virus culture was performed  
57 as a proxy for infectivity.

58

## 59 Results

60 A total of 161 fully vaccinated HCWs diagnosed with COVID-19 by PCR were included in this study. In  
61 accordance with case definitions defined by the Centers for Disease Control and Prevention, infections  
62 were classified as breakthrough infections if the date of the first positive SARS-CoV-2 RT-PCR was more  
63 than 14 days after completion of all recommended vaccine doses<sup>17</sup>. Cases with symptom onset <14 days  
64 after the last vaccine dose and cases with a previous positive test <45 days prior were not considered  
65 breakthrough infections. In parallel with a surge in cases in the general Dutch population<sup>18</sup>, an increased  
66 incidence of breakthrough infections in HCWs was observed in July 2021. In 126 samples a SARS-CoV-2  
67 lineage could be identified, 90.5% of these showed presence of the delta variant. The mean age of the  
68 HCWs with a breakthrough infection was 25.5 years and 91% were less than 50 years old (Table 1). All  
69 infections were mild and did not require hospital admission. The individuals were vaccinated between  
70 January and May 2021 with either an mRNA vaccine or a viral vector vaccine. Table 1 shows the  
71 distribution of vaccines among all HCWs and among the HCWs with breakthrough infections. Although  
72 the data may imply an overrepresentation of Ad26.COVS.2 and BNT162b2 vaccine recipients among the  
73 cases, this study was not designed to compare vaccine effectivity. The indication to receive a certain  
74 vaccine was not random and data on risk factors for exposure were not recorded, therefore potential  
75 confounders could not be adjusted for.

76 Table 1 shows the distribution of Ct-values of the breakthrough infections, as a proxy for the  
77 nasopharyngeal viral load. Ct-values were significantly lower in symptomatic breakthrough infections ( $\mu$   
78 = 23.2) than in asymptomatic breakthrough infections ( $\mu$  = 26.7), corresponding to higher viral loads ( $p$  =  
79 0.022, t-test). In symptomatic vaccinated HCWs, the Ct-values decreased significantly throughout the first  
80 days from symptom onset and were lowest on the third day of illness (Figure 1A). There were no  
81 statistically significant differences in Ct-values between HCWs immunized with the 4 different vaccines.

82 Furthermore, the time since the administration of the last vaccine dose showed no clear relationship with  
83 Ct-values ( $R^2 = 0.02$ ,  $p = 0.13$ , linear regression).

84 Subsequently, RT-PCR positive swabs were tested for the presence of infectious virus using cell culture.  
85 As a reference, we used the (first positive) samples from mild primary infections that occurred in the same  
86 cohort of HCWs prior to the onset of vaccination, these infections were primarily caused by SARS-CoV-2  
87 D614G. The mean Ct-value upon diagnosis was similar between these two groups: 24.6 (15.3 - 33.9) for  
88 vaccinated HCWs and 24.2 (14.53 - 33.8) for unvaccinated HCWs ( $p = 0.53$ , t-test) (Figure 1B). The SARS-  
89 CoV-2 culture of nasopharyngeal swabs was positive in 68.6% of vaccinated HCWs versus 84.9% of  
90 unvaccinated HCWs with primary infections ( $p = 0.005$ , t-test). As the probability of culture positivity  
91 depends on viral load<sup>19</sup>, this was corrected for using a probit regression model with both viral load and  
92 vaccination status as predictors. Figure 1C shows the probability of a positive culture for a given viral load  
93 in vaccinated and unvaccinated HCWs. A positive vaccination status significantly decreased the probability  
94 of culture positivity ( $p = 0.002$ , Wald test).

## 95 **Discussion**

96 In this study we assessed the virological kinetics of mild COVID-19 breakthrough infections upon  
97 immunization with several vaccines. Our data support that the SARS-CoV-2 infectious virus shedding is  
98 lower in vaccinated individuals with breakthrough infections (caused by primarily the delta variant) than  
99 in unvaccinated individuals with primary infections (caused by SARS-CoV-2 D614G). Nevertheless, virus  
100 culture was positive in 68.6% of breakthrough infections and Ct-values decreased throughout the first  
101 three days of illness. Despite the reduced viral viability, the infectivity of individuals with breakthrough  
102 infections should not be neglected.

103 It remains a challenge to assess infectivity of an individual based on clinical sampling. Although RT-PCR is  
104 a highly sensitive method to diagnose SARS-CoV-2 infection, it detects RNA produced in infected cells

105 rather than whole (infectious) virions and is therefore not an optimal indicator of infectivity<sup>19</sup>. Ct-values  
106 are sometimes used to differentiate between phases of infection, but the definition of a cut-off value is  
107 complicated, due to the large variety of assays and clinical samples. Considering these limitations of RT-  
108 PCR, demonstrating viral viability through replication in cell culture is currently considered the best proxy  
109 to demonstrate infectious virus in a clinical specimen<sup>20,21</sup>. We and others previously showed that the  
110 viability of SARS-CoV-2 depends on several factors among which the severity of disease, timing of  
111 sampling, the type of specimen and presence of antibodies<sup>19,22</sup>. To our knowledge this is the first study to  
112 report on virus cultures in COVID-19 vaccine breakthrough infections. Although reduced immune  
113 responses may likely account for breakthrough infections, further studies are needed to investigate  
114 whether these are still able to reduce infectious virus shedding.

115 Obviously, the use of virus culture has its limitations as well: it is a laborious method only performed in  
116 specialized BSL-3 laboratories and therefore not widely applicable. In addition, lack of standardization of  
117 methods (e.g. the cell line used) still hampers interchangeability of results between laboratories.  
118 Nevertheless, an experimental animal study on SARS-CoV-2 transmission recently confirmed a strong  
119 correlation between transmission and virus culture<sup>23</sup>.

120 To study the effect of vaccination on infectivity, it would be preferable to compare infections occurring in  
121 vaccinated and unvaccinated individuals during the same time period, to minimize the impact of different  
122 SARS-CoV-2 variants. Due to the high vaccine coverage in HCW, we diagnosed very few infections in  
123 unvaccinated HCWs. For this reason, we used infections prior to the onset of vaccination as a reference.  
124 Although the predominant SARS-CoV-2 variant differed between groups, the groups were similar with  
125 respect to demographic characteristics, severity of disease, testing algorithms and Ct-values upon  
126 diagnosis. The study participants comprise a population immunized with several vaccines, which reflects  
127 the current situation in many countries. This study was not designed to detect differences in vaccine  
128 effectiveness, as HCWs who received different vaccines also differed with respect to demographic

129 characteristics. The frequency of breakthrough infections in the different groups was likely influenced by  
130 variables that were not controlled for.

131 Phase IV studies have confirmed that vaccination is highly effective at preventing COVID-19-related  
132 morbidity and mortality<sup>2,14,15</sup> although vaccine effectiveness will never reach 100%. Our study supports  
133 the excellent effectiveness of vaccination in preventing severe SARS CoV-2 related disease, but also  
134 demonstrates that vaccinated individuals can still acquire infection and carry infectious virus. Although  
135 symptomatic vaccinated individuals should be tested to further reduce the chance of virus transmission  
136 to individuals at risk for severe disease, further studies are needed to assess whether the decreased  
137 infectious virus shedding in breakthrough infections also lowers the chance of virus transmission.

138

## 139 **Methods**

### 140 **Study population**

141 Data were collected and analyzed anonymously from HCWs of two tertiary care centers in the Netherlands  
142 (Erasmus University Medical Center, Rotterdam and Radboud University Medical Center, Nijmegen),  
143 together employing over 25,000 HCWs. Since April 2020, approximately 1900 symptomatic HCWs  
144 presenting to the occupational health services department were enrolled into a prospective cohort  
145 study<sup>24</sup>. Symptomatic HCWs underwent questioning and SARS-CoV-2 RT-PCR testing, complemented by  
146 tracing and testing of contacts, resulting in detection of asymptomatic cases. Any infections diagnosed by  
147 external laboratories were reported by the department of the respective employee. In both centers,  
148 immunization of HCWs commenced in January 2021 with the BNT162b2 mRNA vaccine (Pfizer-BioNTech),  
149 prioritizing physicians and nurses working directly with COVID-19 cases. The majority of HCWs received  
150 either the mRNA-1273 (Moderna) or Ad26.COV2.S (Janssen) vaccines and a minority was vaccinated with  
151 ChAdOx1 (AstraZeneca Oxford) (Table 1). The indication of the different vaccines was based on availability  
152 and professional role. Throughout the study period, all HCWs with symptomatic breakthrough infections  
153 followed institutional infection prevention guidelines and resumed their professional activities only after  
154 full recovery. HCWs with asymptomatic breakthrough infections remained in home isolation for at least 3  
155 days. We compared virological characteristics of first RT-PCR positive samples collected from HCWs with  
156 breakthrough infections to first RT-PCR positive samples from the same cohort of HCWs prior to the onset  
157 of vaccination. The breakthrough infections occurred between April and July 2021, the primary infections  
158 occurred between April and December 2020 and were primarily caused by SARS-CoV-2 D614G. The two  
159 groups did not differ with respect to demographic characteristics and testing algorithms remained  
160 unchanged.

161



## 162 **RT-PCR for the detection of SARS-CoV-2 RNA**

163 SARS-CoV-2 RT-PCR tests were performed on nasopharyngeal swabs, using the SARS-CoV-2 test on a  
164 Cobas® 6800 system (Roche Diagnostics) in Erasmus MC and using the Aurora Flow (Roche Diagnostics) in  
165 Radboud Medical Center. Using a formula based on E-gene calibration curves, cycle threshold (Ct) values  
166 were converted to viral load in Log<sub>10</sub> RNA copies/mL. This conversion method was previously validated<sup>25</sup>.

## 167 **Typing of SARS-CoV-2 variants using RT-PCR or next generation sequencing**

168 All positive samples were analyzed for the presence of mutations indicative of variants of concern, either  
169 by next generation sequencing or by the use of variant-specific RT-PCR tests (VirSNiP assays 53-0799 and  
170 53-0807, TIB Molbiol, Berlin, Germany) using a SYBR Green melting curve protocol. These assays screen  
171 for the presence of HV69/70 deletion, N501Y, E484K, K417T/K417N and P681R mutations. The results  
172 were interpreted based on the genomics of the SARS-CoV-2 lineages circulating at the time of this study.  
173 The combination of the HV69/70 deletion and N501Y mutation was considered indicative for the Alpha  
174 variant (B.1.1.7). A K417N/E484K/N501Y profile was considered indicative for the Beta variant (B.1.351),  
175 K417T/E484K/N501Y for the Gamma variant (P.1) and P681R for the Delta variant (B.1.617.2).

## 176 **Virus culture**

177 Virus culture was performed on all samples collected in the Erasmus Medical Center, by inoculating Vero  
178 cells (clone 118) as previously described<sup>19</sup>. All cultures were performed in twofold, with one replicate for  
179 immunofluorescence analysis after acetone fixation at 48h of incubation. The second replicate was  
180 microscopically examined for the presence of cytopathic effect daily for 2 weeks. Viral culture was  
181 considered negative if no cytopathic effect was observed after 14 days of incubation. To investigate how  
182 the probability of the binary outcome (culture positivity) depends on viral load and vaccination, the  
183 culture results were analyzed using probit regression.

184 **Statistical analysis**

185 All statistical analyses was performed using R Statistical Software version 4.1.1 (Foundation for Statistical  
186 Computing, Austria) and STATA statistical software program version 13.1 (Statacorp, USA).

187 **Ethical approval**

188 This study was approved by Radboud university medical center Committee on Research Involving Human  
189 Subjects and the Erasmus Medical Center Medical Ethics Committee. All samples were collected following  
190 routine institutional COVID-19 testing guidelines, the participants were not subject to any procedures for  
191 the purpose of this study and all data were anonymized prior to analysis.

192


193

194 **Table 1. Characteristics of health care workers with SARS-CoV-2 vaccine breakthrough infections**

		HCWs with breakthrough infection		All HCWs	
		N	%	N	%
<b>Vaccine</b>	<i>BNT162b2</i>	37	23.0	2537	11.4
	<i>mRNA-1273</i>	38	23.6	11321	51.1
	<i>Ad26.COVS.2.S</i>	71	44.1	7379	33.3
	<i>ChAdOx1</i>	15	9.3	932	4.2
<b>Symptomatic</b>	<i>Yes</i>	136	84,5		
	<i>No</i>	21	13,0		
	<i>Unknown</i>	4	2,5		
<b>Age</b>	<i>&lt;25</i>	71	44,1		
	<i>25-35</i>	56	34,8		
	<i>35-50</i>	20	12,4		
	<i>50-60</i>	10	6,2		
	<i>&gt;60</i>	4	2,5		
<b>Variant</b>	<i>Alpha</i>	10	6,2		
	<i>Beta</i>	1	0,6		
	<i>Gamma</i>	1	0,6		
	<i>Delta</i>	114	70,8		
	<i>Unknown<sup>†</sup></i>	35	21,7		
<b>Ct-value</b>	<i>&lt;15</i>	2	1,2		
	<i>15-20</i>	34	21,1		
	<i>20-25</i>	45	28,0		
	<i>25-30</i>	29	18,0		
	<i>30-35</i>	15	9,3		
	<i>&gt;35</i>	3	1,9		
	<i>Unknown<sup>†</sup></i>	33	20,5		

195

196 <sup>†</sup>Ct-values and variant analysis were not available for health care workers whose tests were performed by external laboratories



**Figure 1. SARS-CoV-2 culture positivity and Ct-values in nasopharyngeal samples of health care workers with SARS-CoV-2 breakthrough infections.** (A) Ct-values by day from symptom onset (B) Ct-values of HCWs with vaccine breakthrough infections (primarily Delta) compared to Ct-values of HCWs with primary infections (primarily D614G) (C) Probability of culture positivity by nasopharyngeal viral load (Probit Analysis), comparing HCWs with vaccine breakthrough infections (primarily Delta) to HCWs with primary infections (primarily D614G)

## References

1. Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* 2020;579:270-3.
2. Abu-Raddad LJ, Chemaitelly H, Butt AA, National Study Group for C-V. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 and B.1.351 Variants. *N Engl J Med* 2021;385:187-9.
3. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. *BMJ* 2021;373:n1088.
4. Bergwerk M, Gonen T, Lustig Y, et al. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. *N Engl J Med* 2021.
5. Kroidl I, Mecklenburg I, Schneiderat P, et al. Vaccine breakthrough infection and onward transmission of SARS-CoV-2 Beta (B.1.351) variant, Bavaria, Germany, February to March 2021. *Euro Surveill* 2021;26.
6. McEwen AE, Cohen S, Bryson-Cahn C, et al. Variants of concern are overrepresented among post-vaccination breakthrough infections of SARS-CoV-2 in Washington State. *Clin Infect Dis* 2021.
7. Rana K, Mohindra R, Pinnaka L. Vaccine Breakthrough Infections with SARS-CoV-2 Variants. *N Engl J Med* 2021;385:e7.
8. Tyagi K, Ghosh A, Nair D, et al. Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility in New Delhi, India. *Diabetes Metab Syndr* 2021;15:1007-8.
9. Vignier N, Berot V, Bonnave N, et al. Breakthrough Infections of SARS-CoV-2 Gamma Variant in Fully Vaccinated Gold Miners, French Guiana, 2021. *Emerg Infect Dis* 2021;27.
10. Absalon J, Koury K, Gruber WC. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. Reply. *N Engl J Med* 2021;384:1578.
11. Baden LR, El Sahly HM, Essink B, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* 2021;384:403-16.
12. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* 2020;383:2603-15.
13. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. *Lancet* 2021;397:99-111.
14. Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. *N Engl J Med* 2021;384:1412-23.
15. Corchado-Garcia J, Puyraimond-Zemmour D, Hughes T, et al. Real-world effectiveness of Ad26.COV2.S adenoviral vector vaccine for COVID-19. *medRxiv* 2021:2021.04.27.21256193.
16. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. *N Engl J Med* 2021;385:585-94.
17. COVID-19 Vaccine Breakthrough Infections Reported to CDC — United States, January 1–April 30, 2021. *MMWR Morb Mortal Wkly Rep* 2021:792–3.
18. RIVM. Epidemiologische situatie van SARS-CoV-2 in Nederland (27 juli 2021). National Institute for Public Health and the Environment 2021.
19. van Kampen JJA, van de Vijver D, Fraaij PLA, et al. Duration and key determinants of infectious virus shedding in hospitalized patients with coronavirus disease-2019 (COVID-19). *Nat Commun* 2021;12:267.
20. Fogueira MD, Luczkowiak J, Lasala F, Perez-Rivilla A, Delgado R. Prolonged SARS-CoV-2 cell culture replication in respiratory samples from patients with severe COVID-19. *Clin Microbiol Infect* 2021;27:886-91.

21. Jefferson T, Spencer EA, Brassey J, Heneghan C. Viral cultures for COVID-19 infectious potential assessment - a systematic review. *Clin Infect Dis* 2020.
22. Wolfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. *Nature* 2020;581:465-9.
23. Sia SF, Yan LM, Chin AWH, et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. *Nature* 2020;583:834-8.
24. Geers D, Shamier MC, Bogers S, et al. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. *Sci Immunol* 2021;6.
25. Schuit E, Veldhuijzen IK, Venekamp RP, et al. Diagnostic accuracy of rapid antigen tests in asymptomatic and presymptomatic close contacts of individuals with confirmed SARS-CoV-2 infection: cross sectional study. *BMJ* 2021;374:n1676.

## **Acknowledgements**

David van de Vijver, Jolanda Kreeft-Voermans, Amber Weevers, Anoushka Comvalius, Djenolan van Mourik and Michael van der Voorden are gratefully acknowledged for their technical and analytical contributions.